Suzhou VAC

Main objectives: (1) To evaluate the immunogenicity and safety of 3-month-old subjects after completing 3 doses of primary immunization and 1 dose of booster immunization. (2) To evaluate the immunogenicity and safety of 6-11-month-old and 12-23-month-old (2-dose group) subjects after completing 2 doses of primary immunization and 2-6-year-old subjects after completing 1 dose of primary immunization. Secondary objectives: (1) To evaluate the immunogenicity and safety of 6-11-month-old subjects after 1 dose of booster immunization. Exploratory objectives: (1) To evaluate the immunogenicity and safety of 12-23-month-old (1-dose group) subjects after completing 1 dose of primary immunization. (2) To evaluate the immune persistence of 3-month-old subjects 12 months and 24 months after completing 1 dose of booster immunization. (3) To evaluate the immune persistence of 6-11-month-old subjects 12 months and 18 months after completing booster immunization. (4) To evaluate the immune persistence of 12-23-month-old subjects 12 months after completing primary immunization. (5) Evaluate the persistence of immunity in subjects aged 2-6 years at 12 months, 24 months and 36 months after completion of basic immunization.

A preliminary observation was conducted on the safety and immunogenicity of the 20-valent pneumococcal conjugate vaccine in healthy people aged 2 months (minimum 6 weeks) to 55 years.

A preliminary observation was conducted on the safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine in healthy people aged 2 months (minimum 6 weeks) to 49 years.